Immunology / Virology & Vaccines

Patient receiving vaccine
#Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Korea #SARS-CoV-2

Adjuvanted Covid-19 vaccine elicits stronger immune response

Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03 relative to the ChAdOx1-S vaccine. The interim results show that GBP510/AS03 had an acceptable safety profile and induced stronger antibody responses when compared with ChAdOx1-S GBP510 is a recombinant… Read More

#News

Close up of vaccine syringe
#Immunology / Virology & Vaccines #Pfizer #United States #Vaccines

US CDC recommends five-in-one meningococcal vaccine

The US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has voted to recommend Pfizer’s Penbraya (meningococcal group A, B, C, W and Y vaccine) for the prevention of the five most common meningococcal serogroups. These serogroups cause the majority of… Read More

#News

Doctor administering a vaccine to patient
#Covid-19 vaccine #Flu vaccine #Immunology / Virology & Vaccines #Influenza #University of Oxford

Oxford study to allow tailoring of Covid-19 and flu vaccines

The Oxford Vaccine Group at the University of Oxford, UK, has launched the LEGACY03 study into human immunity, aimed to improve the design of seasonal vaccines and allow targeting by age group. This study, funded by the Medical Research Council, will test the responses of cells… Read More

#News

#Antibody drug conjugate (ADC) #Cell therapy #Drug discovery #Immunology / Virology & Vaccines #Phase I trial

New DDW Highlights podcast: 30 October 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The news highlights this week feature a variety of treatment approaches, from… Read More

#News

#Antibody drug conjugate (ADC) #Cell therapy #Drug discovery #Immunology / Virology & Vaccines #Phase I trial

This week in drug discovery (23-27 October)  

News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer. My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of… Read More

#News

Hepatitis B
#Gilead Sciences #hepatitis #HOOKIPA Pharma #Immunology / Virology & Vaccines #Preclinical investigations

Preclinical data supports arenaviral therapeutic vaccine for hepatitis B

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability… Read More

#News

Vaccine vial and syringe
#Cancer research #Cancer vaccine #DDW Turning Science into Business Summit #Events #Immunology / Virology & Vaccines #Oncology #Webinar

DDW Cancer Research Summit: Insight on cancer vaccines

The DDW Turning Science into Business Summit, ‘Cancer research opportunities and advances’ will take place online on 16 November at 7AM PST / 10AM EST / 3PM GMT / 4PM CET. This free summit, sponsored by Taconic Biosciences, will offer expert thought leadership… Read More

#Cancer Research #News

Antibodies attack Covid-19
#Covid-19 #Harvard Medical School #Immunology / Virology & Vaccines #Pandemic prevention #Pandemic response #University of Oxford

AI tool predicts new viral variants and could improve vaccines

The UK’s University of Oxford is taking the lead on two collaborative international projects to improve the response to new Covid-19 variants and contribute to future pandemic preparedness. Researchers at Harvard Medical School (HMS) in the US and the University of Oxford have developed a new… Read More

#News #Trending News

#Biotechnology #Funding #Immunology / Virology & Vaccines #MinervaX

Funding to advance maternal vaccine against streptococcus 

MinervaX, a Danish biotechnology company developing a novel, prophylactic vaccine against Group B streptococcus (GBS), has announced the completion of €54 million upsized financing.   GBS is a leading cause of life-threatening infections in newborns as well as adverse pregnancy outcomes such as preterm delivery and stillbirths. Read More

#News

Vaccine
#Covid-19 #Covid-19 vaccine #FDA #Immunology / Virology & Vaccines #Novavax #Omicron

Novavax Covid-19 vaccine updated for XBB.1.5 variant

Novavax has become the next company to have an updated version of its Covid-19 vaccine approved in the US. The Food and Drug Administration (FDA) amended the emergency use authorisation (EUA) of the Novavax Covid-19 Vaccine, Adjuvanted, for use in individuals 12 years of age and… Read More

#News

Mosquito against yellow background
#Immunology / Virology & Vaccines #Malaria #Novavax #Serum Institute of India #University of Oxford #WHO

WHO recommends new cost-effective malaria vaccine

The R21/Matrix-M malaria vaccine has been recommended for use by the World Health Organization’s Strategic Advisory Group of Experts (SAGE) and the Malaria Policy Advisory Group (MPAG). Developed by The University of Oxford and the Serum Institute of India, leveraging Novavax’s adjuvant technology, R21/Matrix-M malaria vaccine demonstrates high efficacy with… Read More

#News #Regulatory #Trending News

Covid-19
#Antivirals #Covid-19 #Covid-19 treatment #Immunology / Virology & Vaccines #Virus mutation

Widely-used antiviral induced SARS-CoV-2 mutations

Researchers have uncovered a link between antiviral drug molnupiravir and a pattern of mutations in the SARS-CoV-2 virus. Molnupiravir induces mutations in the virus’s genome during replication, with the aim of damaging or killing the virus. It was one of the first antivirals available on the… Read More

#Editor's Choice #News

#Covid-19 vaccine #Drug development #Drug discovery #Immunology / Virology & Vaccines #Vaccines

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines… Read More

#News

Influenza
#Immunology / Virology & Vaccines #Influenza #National Institutes of Health (NIH) #Phase I trial

Nanoparticle universal flu vaccine enters Phase I trials

Enrolment in a Phase I trial of a new investigational universal influenza vaccine candidate has begun at the National Institutes of Health’s Clinical Center in Bethesda, Maryland, US. The trial is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH,… Read More

#News

#Covid-19 vaccine #Drug development #Drug discovery #Immunology / Virology & Vaccines #Vaccines

This week in drug discovery (18-22 September)  

News round-up for 18-22 September by DDW Digital Content Editor Diana Spencer. As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines are once again making the headlines, but in the last week we have also reported on vaccine trials for a number of… Read More

#News